What's happening with the FDA and peptides?

Introduction

If you pay attention to the peptide world, you understand what a moving target peptide availability is.

The financial incentives are huge. I have written previously about the huge dollars in the GLP-1 space from big pharma. Although not as large, there is still an impressive amount of money in what I will call GLP-1 knock-offs.

These are the same amino acid sequences. They are manufactured with machinery that sequences the amino acids in a specific order. At times, molecular caps are placed on the ends of the amino acid chains to prevent degradation when they are consumed. That process, although it involves expensive biotechnology equipment, is available not only to big pharma, but also to compounding pharmacists and what is referred to as the gray market or the research-only market.

How Peptides Have Been Accessed

How have peptides been regulated in the past and up until this point? Peptides are short chains of amino acids, many of which occur naturally in your body. Researchers have been studying them for decades for things like healing, inflammation, brain health, sleep, and body composition.

The first way to access peptides was through a doctor. Your physician would write a prescription, and a compounding pharmacy would make the peptide for you. A compounding pharmacy is different from a regular pharmacy. Instead of dispensing mass-produced drugs off a shelf, they custom-make medications for individual patients. This is legal, regulated, and it is not new.

The legal framework that enables this is Section 503A of the Federal Food, Drug, and Cosmetic Act. There is also a Section 503B. That regulation determined that compounding pharmacies can make custom medications using certain approved ingredients, as long as a doctor writes a prescription.

There was another way people accessed peptides. Companies sold peptides labeled for research purposes only or not for human consumption. For years, both pathways coexisted. Doctors prescribed peptides through compounding pharmacies, and people also bought them from research vendors. The research vendors have always been maligned. There is a certain risk you take when you purchase products like that. Purity and contaminants are the primary concerns.

The clinical world gives people medical oversight, quality control, and a doctor monitoring their health. The research world gives people access when the clinical world refuses to provide the product. Both pathways have helped real people get results.

What Changed Under the Biden Administration

The FDA has had a category system since 2017 to classify bulk drug substances nominated for compounding. During the Biden administration, the FDA placed the most popular peptides into the worst category.

Category 1 meant under evaluation. Compounding pharmacies could still work with these substances without too much trouble.

Category 2 was the problem. It meant bulk drug substances that raise significant safety concerns.

Category 3 meant nominated without adequate support. The nominations lacked sufficient evidence.

During the Biden administration, the FDA placed a long list of popular peptides into Category 2. These included most of the popular peptides. The Category 2 label did not make these peptides illegal, but it made life extremely difficult for compounding pharmacies that wanted to make them.

Many compounding pharmacies stopped compounding them entirely because it was not worth the regulatory headache. That meant your doctor could not easily prescribe them either. If your doctor or wellness provider wanted to write you a script for BPC-157, there was no easy way for a pharmacy to fill it.

That loss of access created the research-only space, and many companies were created and rushed to fill the gap. They made absurd amounts of money. Over the last few years, the gray market has exploded. Research peptide companies became the primary way most people accessed these compounds.

This left us in a weird middle ground where the clinical pathway was choked off, and the research pathway was the only practical option.

Yesterday and the day before, the FDA released 2 documents. I wrote this late on April 16.

The first document came out yesterday, April 15. The FDA updated its 503A Categories list and announced that it is removing all of the following peptides from Category 2: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon, GHK-Cu (injectable), LL-37, Dihexa, PEG-MGF, and Melanotan II.

The second document came out today, April 16. The FDA published a Federal Register notice announcing a formal meeting of the Pharmacy Compounding Advisory Committee, or PCAC. The meeting is scheduled for July 23 and 24, 2026, at the FDA's White Oak Campus in Silver Spring, Maryland.

At that meeting, the Committee will review 7 of those 12 peptides for potential inclusion on the 503A Bulk Drug Substances List.

July 23:

BPC-157 is being evaluated for ulcerative colitis.

KPV is being evaluated for wound healing and inflammatory conditions.

TB-500 is being evaluated for wound healing.

MOTS-c is being evaluated for obesity and osteoporosis.

July 24:

DSIP is being evaluated for opioid withdrawal, chronic insomnia, and narcolepsy.

Semax is being evaluated for cerebral ischemia, migraine, and trigeminal neuralgia.

Epitalon is being evaluated for insomnia.

The remaining 5, GHK-Cu, LL-37, Dihexa, PEG-MGF, and Melanotan II, are scheduled for PCAC review before the end of February 2027.

What the Implications Look Like

These peptides are not becoming FDA-approved drugs.

The FDA is considering whether compounding pharmacies should be allowed to make these peptides without the regulatory cloud and uncertainty that has hung over them for the past few years. If the PCAC recommends them for the 503A list, compounding pharmacies can manufacture them openly.

Doctors can prescribe them without worrying about their pharmacy getting shut down. Patients will be able to access them through a legitimate clinical pathway. Think of it this way. The door to getting peptides from your doctor has been mostly closed. This process could reopen it.

Peptides should become more accessible through clinics. The providers that move first will be the ones already working with peptides. Those are the med spas, wellness clinics, and hormone replacement clinics. These are the doctors and practices that already understand peptides and already have patients asking about them. Once the regulatory pressure lifts, they will start offering peptides again.

Expect the initial prices to remain at current levels, but also expect that legitimacy and competition will bring prices down. At first, getting peptides through your doctor will probably cost more than what you are paying for research-purpose-only peptides.

However, these peptides are not likely to be patented drugs. They are compounded substances. When you have open competition and rising supply, prices fall. That is just how markets work. Over time, expect prices to come down as these peptide molecules become even more prevalent than they already are.

The economic incentives will shift. When you can get a quality-controlled peptide from your doctor for roughly the same price as ordering from a research vendor, most people are going to choose the doctor avenue.

Think about metformin. Metformin is so easy and affordable to get from a doctor that most people just do not have a reason to source it from a research company. The prescription pathway is simple and cheap. The incentive to go the research route to save money goes away as the clinical route becomes affordable.

If you are someone who buys research peptides right now, I understand why this news might make you nervous. You are wondering if the FDA is about to shut down the vendors you rely on.

The gray market is pretty entrenched right now. Many people buy research peptides. A lot of companies sell them. That infrastructure has been built over the years. It does not just vanish because the FDA schedules a meeting. Research peptides existed before the Category 2 intervention.

It might be harder to find certain peptides from research companies. You might have to use alternative payment methods. You might need to be in private groups where people share what is available and who is reliable.

Some people will prefer the clinical route. Some will prefer the research route. Some will use both depending on the compound. These changes will not move at blinding speed. It will evolve over time.

The tipping point comes when the clinical pathway is so easy and so affordable that buying research peptides just does not make practical sense for most people anymore. When your doctor can prescribe it for roughly the same cost, most people will choose that route. It is just basic economics.

The Dates to Watch

The FDA opened a public docket in anticipation of this July meeting. This is essentially a comment section, which means you can submit comments that real people at the FDA will actually read.

Key dates to watch:

June 30, 2026 is the deadline to request to speak at the meeting.

July 9, 2026 is the deadline for written comments to reach Committee members before the meeting.

July 22, 2026 is the final deadline for all comments.

If you have participated in the Peptide Safety Initiative, this is the moment that data was designed for. The FDA wants to know if these compounds are safe enough for compounding. They will be evaluating our data at the meeting.

That’s where we are now.

Peptides are becoming more accessible, more normalized, and the clinical pathway is opening up.

Eventually, the economics will align so that most people can get what they need through a provider they trust at a price that makes sense.